{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:25:49Z","timestamp":1793388349317,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004721","name":"University of Tokyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18ck0106416"],"award-info":[{"award-number":["JP18ck0106416"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20lm0203140"],"award-info":[{"award-number":["JP20lm0203140"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.omto.2023.07.002","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T02:37:48Z","timestamp":1689734268000},"page":"72-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Neoadjuvant use of oncolytic herpes virus G47\u0394 prevents local recurrence after insufficient resection in tongue cancer models"],"prefix":"10.1016","volume":"30","author":[{"given":"Kosuke","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-8010","authenticated-orcid":false,"given":"Tomoki","family":"Todo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2023.07.002_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hed.26504","article-title":"Impact of treatment delay on survival of oral\/oropharyngeal cancers: Results of a nationwide screening program","volume":"43","author":"Su","year":"2021","journal-title":"Head Neck"},{"key":"10.1016\/j.omto.2023.07.002_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoto.2016.4238","article-title":"A Proposal to Redefine Close Surgical Margins in Squamous Cell Carcinoma of the Oral Tongue","volume":"143","author":"Zanoni","year":"2017","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.omto.2023.07.002_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12957-018-1308-7","article-title":"Effect of neoadjuvant chemotherapy and its correlation with HPV status, EGFR, Her-2-neu, and GADD45 expression in oral squamous cell carcinoma","volume":"16","author":"Pandey","year":"2018","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.omto.2023.07.002_bib4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omto.2023.07.002_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.omto.2020.12.007","article-title":"Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma","volume":"20","author":"Takano","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib6","article-title":"A new oncolytic V accinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery","volume":"8","author":"Ahmed","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2023.07.002_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omto.2017.05.002","article-title":"Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma","volume":"5","author":"Jaime-Ramirez","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib8","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.ymthe.2017.09.010","article-title":"Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T\u00a0cells against Metastatic Head and Neck Cancer","volume":"25","author":"Rosewell Shaw","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2023.07.002_bib9","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/hed.25642","article-title":"Oncolytic Sendai virus-induced tumor-specific immunoresponses suppress \u201csimulated metastasis\u201d of squamous cell carcinoma in an immunocompetent mouse model","volume":"41","author":"Tanaka","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.omto.2023.07.002_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.07.002_bib11","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1073\/pnas.101136398","article-title":"Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing","volume":"98","author":"Todo","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2023.07.002_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12985-020-01362-6","article-title":"The role of host eIF2\u03b1 in viral infection","volume":"21","author":"Liu","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.omto.2023.07.002_bib13","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1073\/pnas.89.8.3266","article-title":"The gamma 1 (34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells","volume":"89","author":"Chou","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omto.2023.07.002_bib14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.3390\/ijms22041626","article-title":"Hiltonol Cocktail Kills Lung Cancer Cells by Activating Cancer-Suppressors, PKR\/OAS, and Restraining the Tumor Microenvironment","volume":"22","author":"Chang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omto.2023.07.002_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1128\/jvi.62.1.196-205.1988","article-title":"Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant","volume":"62","author":"Goldstein","year":"1988","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omto.2023.07.002_bib16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0092-8674(94)90215-1","article-title":"A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes","volume":"77","author":"York","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.omto.2023.07.002_bib17","doi-asserted-by":"crossref","first-page":"7886","DOI":"10.1158\/1078-0432.CCR-05-1090","article-title":"Oncolytic herpes simplex virus vector G47\u0394 in combination with androgen ablation for the treatment of human prostate adenocarcinoma","volume":"11","author":"Fukuhara","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2023.07.002_bib18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.7314\/APJCP.2015.16.3.1241","article-title":"Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus","volume":"16","author":"Wang","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.omto.2023.07.002_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omto.2020.03.022","article-title":"Efficacy of a third-generation oncolytic herpes virus G47\u0394 in advanced stage models of human gastric cancer","volume":"17","author":"Sugawara","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.omto.2021.10.012","article-title":"Efficacy and safety of a third-generation oncolytic herpes virus G47\u0394 in models of human esophageal carcinoma","volume":"23","author":"Yajima","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omto.2022.12.001","article-title":"Overcoming resistance of stoma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47\u0394 and immune checkpoint inhibitors","volume":"28","author":"Yamada","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib22","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u0394 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omto.2023.07.002_bib23","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2023.07.002_bib24","article-title":"The use of oncolytic virotherapy in the neoadjuvant setting","volume":"10","author":"Thomas","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omto.2023.07.002_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.cgt.7700558","article-title":"Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection","volume":"10","author":"Jarnagin","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omto.2023.07.002_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.omto.2020.11.002","article-title":"A novel vaccinia virus enhances anti-tumor efficacy and promotes a long-term anti-tumor response in a murine model of colorectal cancer","volume":"20","author":"Wang","year":"2021","journal-title":"Mol. Ther. Oncolytic"},{"key":"10.1016\/j.omto.2023.07.002_bib27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hed.25466","article-title":"Classification of GLOSSECTOMIES: Proposal for tongue cancer resections","volume":"41","author":"Ansarin","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.omto.2023.07.002_bib28","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoto.2015.1351","article-title":"Early Oral Tongue Squamous Cell Carcinoma Sampling of Margins From Tumor Bed and Worse Local Control","volume":"141","author":"Maxwell","year":"2015","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.omto.2023.07.002_bib29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jamaoto.2013.5892","article-title":"Efficacy of induction selection chemotherapy vs primary surgery for patients with advanced oral cavity carcinoma","volume":"140","author":"Chinn","year":"2014","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.omto.2023.07.002_bib30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3892\/or_00000463","article-title":"The effect of neoadjuvant therapy on the 5-fluorouracil metabolic and relative enzymes of oral squamous cell carcinoma","volume":"22","author":"Yamashita","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2023.07.002_bib31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1200\/JCO.2012.43.8820","article-title":"Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma","volume":"31","author":"Zhong","year":"2013","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.07.002_bib32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/0019-509X.178442","article-title":"Does the use of induction chemotherapy in oral cavity cancer compromise subsequent loco-regional treatment delivery: Results from a matched pair analysis","volume":"52","author":"Patil","year":"2015","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.omto.2023.07.002_bib33","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.2013.54.6309","article-title":"Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer","volume":"32","author":"Cohen","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2023.07.002_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103569","article-title":"Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective","volume":"169","author":"Cabezas-Camarero","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omto.2023.07.002_bib35","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41199-020-00052-8","article-title":"The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC","volume":"5","author":"Stafford","year":"2020","journal-title":"Cancers Head Neck"},{"key":"10.1016\/j.omto.2023.07.002_bib36","article-title":"Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma","volume":"2","author":"Knochelmann","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omto.2023.07.002_bib37","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2023.07.002_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104849","article-title":"Nonsurgical management of resectable oral cavity cancer in the wake of COVID-19: A rapid review and meta-analysis","volume":"109","author":"Forner","year":"2020","journal-title":"Oral Oncol."},{"key":"10.1016\/j.omto.2023.07.002_bib39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/biomedicines8110484","article-title":"Induction of Durable Antitumor Response by a Novel Oncolytic Herpesvirus Expressing Multiple Immunomodulatory Transgenes","volume":"8","author":"Chouljenko","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.omto.2023.07.002_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/v8020043","article-title":"To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses","volume":"8","author":"Cassady","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.omto.2023.07.002_bib41","article-title":"Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity","volume":"1","author":"Leddon","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib42","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1089\/10430349950016483","article-title":"Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus","volume":"10","author":"Todo","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omto.2023.07.002_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.omto.2020.08.010","article-title":"Neoadjuvant Use of Oncolytic Herpes Virus G47\u0394 Enhances the Antitumor Efficacy of Radiofrequency Ablation","volume":"18","author":"Yamada","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib44","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.omto.2021.06.008","article-title":"Oncolytic herpes virus G47\u0394 injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis","volume":"22","author":"Uchihashi","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omto.2023.07.002_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/23320885.2021.1884559","article-title":"Analysis of speech and swallowing and quality of life in patients undergoing subtotal glossectomy with free flap reconstruction followed by radiotherapy","volume":"8","author":"Mantelakis","year":"2021","journal-title":"Case Rep. Plast. Surg. Hand Surg."},{"key":"10.1016\/j.omto.2023.07.002_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40463-017-0234-y","article-title":"Functional and quality of life outcomes after partial glossectomy: a multi-institutional longitudinal study of the head and neck research network","volume":"46","author":"Dzioba","year":"2017","journal-title":"J.\u00a0Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.omto.2023.07.002_bib47","first-page":"2004","article-title":"Transcriptome analysis of tongue cancer based on high-throughput sequencing","volume":"43","author":"Tang","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.omto.2023.07.002_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071932","article-title":"STAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells","volume":"8","author":"Okemoto","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omto.2023.07.002_bib49","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omto.2023.07.002_bib50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2372770523000487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:24:57Z","timestamp":1762496697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2372770523000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":50,"alternative-id":["S2372770523000487"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2023.07.002","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant use of oncolytic herpes virus G47\u0394 prevents local recurrence after insufficient resection in tongue cancer models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2023.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}